JP2005528406A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005528406A5 JP2005528406A5 JP2003586149A JP2003586149A JP2005528406A5 JP 2005528406 A5 JP2005528406 A5 JP 2005528406A5 JP 2003586149 A JP2003586149 A JP 2003586149A JP 2003586149 A JP2003586149 A JP 2003586149A JP 2005528406 A5 JP2005528406 A5 JP 2005528406A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- compound
- nhc
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 69
- 150000001875 compounds Chemical class 0.000 claims 27
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 10
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 208000007536 Thrombosis Diseases 0.000 claims 6
- 239000002327 cardiovascular agent Substances 0.000 claims 5
- 229940125692 cardiovascular agent Drugs 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 206010002383 Angina Pectoris Diseases 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 201000006474 Brain Ischemia Diseases 0.000 claims 4
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 4
- 206010014498 Embolic stroke Diseases 0.000 claims 4
- 206010018364 Glomerulonephritis Diseases 0.000 claims 4
- 206010019280 Heart failures Diseases 0.000 claims 4
- 206010020772 Hypertension Diseases 0.000 claims 4
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 4
- 206010043647 Thrombotic Stroke Diseases 0.000 claims 4
- 206010003119 arrhythmia Diseases 0.000 claims 4
- 230000006793 arrhythmia Effects 0.000 claims 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 4
- 206010008118 cerebral infarction Diseases 0.000 claims 4
- 125000001188 haloalkyl group Chemical group 0.000 claims 4
- 208000010125 myocardial infarction Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000037803 restenosis Diseases 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 3
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims 3
- -1 methylenedioxy Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims 2
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 208000013557 cerebral hemisphere cancer Diseases 0.000 claims 2
- 201000008860 cerebrum cancer Diseases 0.000 claims 2
- 229960003009 clopidogrel Drugs 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 claims 1
- 229940123073 Angiotensin antagonist Drugs 0.000 claims 1
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 claims 1
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 claims 1
- 102000002045 Endothelin Human genes 0.000 claims 1
- 108050009340 Endothelin Proteins 0.000 claims 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 claims 1
- 101710149643 Integrin alpha-IIb Proteins 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical group OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 1
- 102000003790 Thrombin receptors Human genes 0.000 claims 1
- 108090000166 Thrombin receptors Proteins 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 239000002369 angiotensin antagonist Substances 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 229960003958 clopidogrel bisulfate Drugs 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims 1
- 239000002792 enkephalinase inhibitor Substances 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 claims 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 claims 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37307202P | 2002-04-16 | 2002-04-16 | |
| PCT/US2003/011510 WO2003089428A1 (en) | 2002-04-16 | 2003-04-14 | Tricyclic thrombin receptor antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010049903A Division JP2010132710A (ja) | 2002-04-16 | 2010-03-05 | 三環式トロンビンレセプターアンタゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005528406A JP2005528406A (ja) | 2005-09-22 |
| JP2005528406A5 true JP2005528406A5 (https=) | 2009-08-13 |
| JP4558331B2 JP4558331B2 (ja) | 2010-10-06 |
Family
ID=29250954
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003586149A Expired - Fee Related JP4558331B2 (ja) | 2002-04-16 | 2003-04-14 | 三環式トロンビンレセプターアンタゴニスト |
| JP2010049903A Withdrawn JP2010132710A (ja) | 2002-04-16 | 2010-03-05 | 三環式トロンビンレセプターアンタゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010049903A Withdrawn JP2010132710A (ja) | 2002-04-16 | 2010-03-05 | 三環式トロンビンレセプターアンタゴニスト |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US7304078B2 (https=) |
| EP (5) | EP1495018B3 (https=) |
| JP (2) | JP4558331B2 (https=) |
| KR (1) | KR101026929B1 (https=) |
| CN (1) | CN1659162B (https=) |
| AR (1) | AR039570A1 (https=) |
| AT (3) | ATE494284T1 (https=) |
| AU (1) | AU2003221932B2 (https=) |
| BR (1) | BRPI0309309B8 (https=) |
| CA (1) | CA2482858C (https=) |
| CY (3) | CY1107184T1 (https=) |
| DE (3) | DE60335679D1 (https=) |
| DK (2) | DK2065384T3 (https=) |
| EC (1) | ECSP045368A (https=) |
| ES (3) | ES2338171T3 (https=) |
| FR (1) | FR15C0047I2 (https=) |
| IL (1) | IL164585A (https=) |
| LT (1) | LTC1495018I2 (https=) |
| LU (1) | LU92759I2 (https=) |
| MX (1) | MXPA04010308A (https=) |
| MY (1) | MY144040A (https=) |
| NL (1) | NL300746I2 (https=) |
| NO (2) | NO330500B1 (https=) |
| NZ (2) | NZ575139A (https=) |
| PE (1) | PE20040412A1 (https=) |
| PL (1) | PL214718B1 (https=) |
| PT (2) | PT1495018E (https=) |
| RU (2) | RU2329264C9 (https=) |
| SG (1) | SG164279A1 (https=) |
| SI (2) | SI1495018T1 (https=) |
| TW (1) | TWI343919B (https=) |
| WO (1) | WO2003089428A1 (https=) |
| ZA (1) | ZA200408342B (https=) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6346510B1 (en) | 1995-10-23 | 2002-02-12 | The Children's Medical Center Corporation | Therapeutic antiangiogenic endostatin compositions |
| US7235567B2 (en) * | 2000-06-15 | 2007-06-26 | Schering Corporation | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
| US7488742B2 (en) * | 2000-06-15 | 2009-02-10 | Schering Corporation | Thrombin receptor antagonists |
| US20040192753A1 (en) * | 2000-06-15 | 2004-09-30 | Samuel Chackalamannil | Methods of use of thrombin receptor antagonists |
| CN1984905B (zh) * | 2004-05-28 | 2011-06-22 | 先灵公司 | 作为凝血酶受体拮抗剂的约束喜巴辛类似物 |
| US8563511B2 (en) * | 2004-10-06 | 2013-10-22 | University Of Rochester | Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway |
| WO2006076452A2 (en) * | 2005-01-14 | 2006-07-20 | Schering Corporation | An exo-selective synthesis of himbacine analogs |
| CA2875768C (en) | 2005-01-14 | 2018-03-06 | George G. Wu | Process for the preparation of phosphonate compounds useful in the preparation of himbacine analogs |
| DE602006020414D1 (en) * | 2005-01-14 | 2011-04-14 | Schering Corp | Synthese von himbacinanaloga |
| JP2008526254A (ja) * | 2005-01-14 | 2008-07-24 | シェーリング コーポレイション | ヒンバシン類似物のキラルプロパルギルアルコールおよびエステル中間体の調製 |
| US7541471B2 (en) * | 2005-01-14 | 2009-06-02 | Schering Corporation | Synthesis of himbacine analogs |
| US7776889B2 (en) * | 2005-03-31 | 2010-08-17 | Schering Corporation | Spirocyclic thrombin receptor antagonists |
| WO2007075808A2 (en) * | 2005-12-20 | 2007-07-05 | Schering Corporation | Methods for preventing and/or treating a cell proliferative disorder |
| JP2009521472A (ja) * | 2005-12-22 | 2009-06-04 | シェーリング コーポレイション | 心肺手術の合併症の予防としてのトロンビンレセプターアンタゴニスト |
| TW200812619A (en) * | 2006-04-06 | 2008-03-16 | Schering Corp | TRA combination therapies |
| US8003803B2 (en) | 2006-04-13 | 2011-08-23 | Schering Corporation | Fused ring thrombin receptor antagonists |
| EP2032560B1 (en) * | 2006-06-29 | 2013-05-01 | Merck Sharp & Dohme Corp. | Substituted bicyclic and tricyclic thrombin receptor antagonists |
| TWI367112B (en) * | 2006-06-30 | 2012-07-01 | Schering Corp | Immediate-release tablet formulations of a thrombin receptor antagonist |
| AR061727A1 (es) * | 2006-06-30 | 2008-09-17 | Schering Corp | Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato |
| DE102006036023A1 (de) | 2006-08-02 | 2008-02-07 | Sanofi-Aventis | Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität |
| TWI343262B (en) * | 2006-09-26 | 2011-06-11 | Schering Corp | Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist |
| CA2666903A1 (en) * | 2006-10-04 | 2008-05-22 | Schering Corporation | Thrombin receptor antagonists based on the modified tricyclic unit of himbacine |
| EP2069326B1 (en) | 2006-10-04 | 2015-03-18 | Merck Sharp & Dohme Corp. | Bicyclic and tricyclic derivatives as thrombin receptor antagonists |
| EP2120879A2 (en) * | 2006-12-22 | 2009-11-25 | Schering Corporation | Disintegration promoters in solid dose wet granulation formulations |
| BRPI0809095A2 (pt) * | 2007-03-23 | 2014-09-09 | Schering Corp | Redução de eventos adversos após intervenção percutânea através de uso de um antagonista de receptor de trombina |
| RU2494100C2 (ru) | 2008-02-05 | 2013-09-27 | Санофи-Авентис | Соли триазолия в качестве ингибиторов par1, их получение и применение в качестве лекарственного средства |
| RS52264B (sr) | 2008-02-05 | 2012-10-31 | Sanofi | Triazolopiridazini kao inhibitori par1, njihovo dobijanje i upotreba kao lekova |
| WO2009124103A2 (en) * | 2008-04-02 | 2009-10-08 | Schering Corporation | Combination therapies comprising par1 antagonists with par4 antagonists |
| EP2805939B1 (en) | 2008-05-19 | 2018-06-27 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as factor IXA inhibitors. |
| EP2438060B1 (en) * | 2009-06-04 | 2013-10-02 | Merck Sharp & Dohme Corp. | Active metabolite of a thrombin receptor antagonist |
| JP2012529431A (ja) | 2009-06-08 | 2012-11-22 | メルク・シャープ・アンド・ドーム・コーポレーション | トロンビン受容体アンタゴニストおよびクロピドグレルの固定用量錠剤 |
| WO2011017296A1 (en) | 2009-08-04 | 2011-02-10 | Schering Corporation | 4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors |
| ES2532902T3 (es) | 2010-04-16 | 2015-04-01 | Sanofi | Piridil-vinil-pirroles tricíclicos como inhibidores de PAR1 |
| WO2011128420A1 (de) | 2010-04-16 | 2011-10-20 | Sanofi | Pyridyl-vinyl-pyrazolo-chinoline als par1-inhibitoren |
| KR101303348B1 (ko) | 2010-06-25 | 2013-09-03 | 한국화학연구원 | 트롬빈 수용체 길항제인 ［6＋5］접합 바이사이클, 그의 제조방법 및 그를 포함하는 약제학적 조성물 |
| WO2013134012A1 (en) | 2012-03-06 | 2013-09-12 | Merck Sharp & Dohme Corp. | Preparation and use of bicyclic himbacine derivatives as par-receptor antagonists |
| WO2015013083A1 (en) * | 2013-07-22 | 2015-01-29 | Merck Sharp & Dohme Corp. | Co-crystal of the par-1 receptor antagonist vorapaxar and aspirin |
| EP3035928B1 (en) * | 2013-08-22 | 2023-10-18 | Merck Sharp & Dohme LLC | 3'-pyridyl substituted- 6,6-difluoro bicyclic himbacine derivatives |
| EP3035929B1 (en) * | 2013-08-22 | 2024-07-03 | Merck Sharp & Dohme LLC | 7a-amide substituted-6,6-difluoro bicyclic himbacine derivatives |
| WO2015026685A1 (en) * | 2013-08-22 | 2015-02-26 | Merck Sharp & Dohme Corp. | 7a-heterocycle substituted- 6, 6-difluoro bicyclic himbacine derivatives |
| FR3014693B1 (fr) | 2013-12-16 | 2016-01-08 | Pf Medicament | Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales |
| WO2015160636A1 (en) | 2014-04-16 | 2015-10-22 | Merck Sharp & Dohme Corp. | Factor ixa inhibitors |
| DE102014108210A1 (de) | 2014-06-11 | 2015-12-17 | Dietrich Gulba | Rodentizid |
| CN105985303B (zh) * | 2015-02-13 | 2020-08-14 | 上海彩迩文生化科技有限公司 | 抗凝血剂的制备方法、中间体及其制备方法 |
| CN106478608A (zh) * | 2015-09-01 | 2017-03-08 | 博瑞生物医药（苏州）股份有限公司 | 沃拉帕沙的硫酸盐的结晶多晶型物 |
| CN106749201A (zh) * | 2015-11-25 | 2017-05-31 | 博瑞生物医药（苏州）股份有限公司 | 一种沃拉帕沙及其中间体的制备方法 |
| TR201601548A2 (tr) * | 2016-02-05 | 2018-03-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Vorapaksar ve metoprololün bi̇r farmasöti̇k kompozi̇syonu |
| WO2017134200A1 (en) * | 2016-02-05 | 2017-08-10 | Sanovel Ilac Sanayi Ve Ticaret A.S. | A novel pharmaceutical composition of vorapaxar and metoprolol |
| TW201738221A (zh) * | 2016-04-22 | 2017-11-01 | Jiangsu Tasly Diyi Pharmaceutical Co Ltd | 新的喜巴辛類似物、其藥物組合物及其在醫藥中的應用 |
| CN106236779A (zh) * | 2016-08-22 | 2016-12-21 | 孔五 | 一种脐带血富血小板血浆prp的制备方法 |
| FR3090317B1 (fr) | 2018-12-19 | 2021-05-07 | Cvasthera | Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale |
| CN110407819B (zh) * | 2019-08-02 | 2020-06-26 | 牡丹江医学院 | 一种作为预防外科手术并发症的凝血酶受体拮抗剂 |
| US20210113536A1 (en) * | 2019-10-21 | 2021-04-22 | United States Government as Represented by the Department of Veteran Affairs | Methods and compositions for detecting and treating venous thromboembolism |
| FR3109089B1 (fr) | 2020-04-08 | 2023-04-14 | Cvasthera | Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales |
| CN116133660B (zh) | 2020-07-22 | 2025-05-02 | 詹森药业有限公司 | 可用作因子XIa抑制剂的化合物 |
| US11814364B2 (en) | 2021-03-18 | 2023-11-14 | Janssen Pharmaceutica Nv | Pyridine N-oxide derivatives useful as factor XIa inhibitors |
| US11919881B2 (en) | 2021-03-18 | 2024-03-05 | Janssen Pharmaceutica Nv | Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors |
| US11845748B2 (en) | 2021-03-18 | 2023-12-19 | Janssen Pharmaceutica Nv | Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors |
| EP4070658A1 (de) | 2021-04-06 | 2022-10-12 | BIORoxx GmbH | Verwendung von blutgerinnungshemmenden verbindungen als rodentizide |
| US11897880B2 (en) | 2021-04-30 | 2024-02-13 | Janssen Pharmaceutica Nv | 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors |
| US12286429B2 (en) | 2021-07-22 | 2025-04-29 | Janssen Pharmaceutica Nv | 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide derivatives useful as a factor XIa inhibitors |
| US11958856B2 (en) | 2021-07-22 | 2024-04-16 | Janssen Pharmaceutica Nv | Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors |
| FR3134314A1 (fr) | 2022-04-08 | 2023-10-13 | Cvasthera | Composition pharmaceutique à base de vorapaxar et son utilisation pour le traitement des maladies inflammatoires intestinales |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2623810B2 (fr) | 1987-02-17 | 1992-01-24 | Sanofi Sa | Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant |
| TW197435B (https=) * | 1990-11-22 | 1993-01-01 | Takeda Pharm Industry Co Ltd | |
| GB9102862D0 (en) * | 1991-02-11 | 1991-03-27 | Erba Carlo Spa | N-imidazolyl derivatives of substituted or alkoxymino tetrahydronaphthalenes and chromans |
| IL106197A (en) | 1992-07-30 | 1999-11-30 | Cor Therapeutics Inc | Agagonists for the rhombin receptors and pharmaceutical preparations containing them |
| US5576328A (en) | 1994-01-31 | 1996-11-19 | Elf Sanofi | Method for the secondary prevention of ischemic events |
| US6063847A (en) | 1997-11-25 | 2000-05-16 | Schering Corporation | Thrombin receptor antagonists |
| CZ298578B6 (cs) * | 1997-11-25 | 2007-11-14 | Schering Corporation | Heterocyklickou skupinou substituovaná tricyklická sloucenina a farmaceutický prostredek ji obsahující |
| FR2779726B1 (fr) | 1998-06-15 | 2001-05-18 | Sanofi Sa | Forme polymorphe de l'hydrogenosulfate de clopidogrel |
| US20040192753A1 (en) * | 2000-06-15 | 2004-09-30 | Samuel Chackalamannil | Methods of use of thrombin receptor antagonists |
| AU6690001A (en) | 2000-06-15 | 2001-12-24 | Schering Corp | Thrombin receptor antagonists |
| US7488742B2 (en) * | 2000-06-15 | 2009-02-10 | Schering Corporation | Thrombin receptor antagonists |
| KR100960170B1 (ko) | 2001-10-18 | 2010-05-26 | 쉐링 코포레이션 | 트롬빈 수용체 길항제로서의 힘바신 동족체 |
-
2003
- 2003-04-14 BR BRPI0309309A patent/BRPI0309309B8/pt not_active IP Right Cessation
- 2003-04-14 NZ NZ575139A patent/NZ575139A/en not_active IP Right Cessation
- 2003-04-14 US US10/412,982 patent/US7304078B2/en active Active
- 2003-04-14 DE DE60335679T patent/DE60335679D1/de not_active Expired - Lifetime
- 2003-04-14 MY MYPI20031400A patent/MY144040A/en unknown
- 2003-04-14 SI SI200331110T patent/SI1495018T1/sl unknown
- 2003-04-14 ES ES07016461T patent/ES2338171T3/es not_active Expired - Lifetime
- 2003-04-14 MX MXPA04010308A patent/MXPA04010308A/es active IP Right Grant
- 2003-04-14 KR KR1020047016409A patent/KR101026929B1/ko not_active Expired - Fee Related
- 2003-04-14 NZ NZ535880A patent/NZ535880A/en not_active IP Right Cessation
- 2003-04-14 SG SG200607217-7A patent/SG164279A1/en unknown
- 2003-04-14 SI SI200331969T patent/SI2065384T1/sl unknown
- 2003-04-14 EP EP03718393A patent/EP1495018B3/en not_active Expired - Lifetime
- 2003-04-14 PT PT03718393T patent/PT1495018E/pt unknown
- 2003-04-14 AT AT09150995T patent/ATE494284T1/de active
- 2003-04-14 ES ES09150995T patent/ES2357876T3/es not_active Expired - Lifetime
- 2003-04-14 AT AT03718393T patent/ATE378330T1/de active
- 2003-04-14 EP EP09150996A patent/EP2062890B1/en not_active Expired - Lifetime
- 2003-04-14 EP EP07016461A patent/EP1860106B1/en not_active Expired - Lifetime
- 2003-04-14 DE DE60317493.0T patent/DE60317493T3/de not_active Expired - Lifetime
- 2003-04-14 RU RU2004133375/04A patent/RU2329264C9/ru active
- 2003-04-14 AU AU2003221932A patent/AU2003221932B2/en not_active Ceased
- 2003-04-14 ES ES03718393T patent/ES2297150T7/es active Active
- 2003-04-14 EP EP09150995A patent/EP2065384B1/en not_active Expired - Lifetime
- 2003-04-14 CA CA2482858A patent/CA2482858C/en not_active Expired - Lifetime
- 2003-04-14 DK DK09150995.0T patent/DK2065384T3/da active
- 2003-04-14 PT PT09150995T patent/PT2065384E/pt unknown
- 2003-04-14 DE DE60331114T patent/DE60331114D1/de not_active Expired - Lifetime
- 2003-04-14 PL PL373332A patent/PL214718B1/pl unknown
- 2003-04-14 AT AT07016461T patent/ATE455774T1/de not_active IP Right Cessation
- 2003-04-14 JP JP2003586149A patent/JP4558331B2/ja not_active Expired - Fee Related
- 2003-04-14 EP EP08012015A patent/EP1982984B1/en not_active Expired - Lifetime
- 2003-04-14 AR ARP030101302A patent/AR039570A1/es active IP Right Grant
- 2003-04-14 CN CN038131129A patent/CN1659162B/zh not_active Expired - Fee Related
- 2003-04-14 PE PE2003000375A patent/PE20040412A1/es active IP Right Grant
- 2003-04-14 DK DK03718393T patent/DK1495018T3/da active
- 2003-04-14 WO PCT/US2003/011510 patent/WO2003089428A1/en not_active Ceased
- 2003-04-15 TW TW092108648A patent/TWI343919B/zh not_active IP Right Cessation
-
2004
- 2004-10-14 IL IL164585A patent/IL164585A/en active IP Right Grant
- 2004-10-14 ZA ZA200408342A patent/ZA200408342B/xx unknown
- 2004-10-15 EC EC2004005368A patent/ECSP045368A/es unknown
- 2004-11-15 NO NO20044963A patent/NO330500B1/no not_active IP Right Cessation
-
2007
- 2007-04-10 US US11/733,635 patent/US7713999B2/en not_active Expired - Lifetime
- 2007-07-06 US US11/774,358 patent/US20070270439A1/en not_active Abandoned
-
2008
- 2008-02-07 CY CY20081100152T patent/CY1107184T1/el unknown
- 2008-02-21 RU RU2008106401/04A patent/RU2008106401A/ru not_active Application Discontinuation
-
2010
- 2010-03-05 JP JP2010049903A patent/JP2010132710A/ja not_active Withdrawn
-
2011
- 2011-03-30 CY CY20111100338T patent/CY1111363T1/el unknown
-
2015
- 2015-06-29 LU LU92759C patent/LU92759I2/xx unknown
- 2015-06-29 NL NL300746C patent/NL300746I2/nl unknown
- 2015-07-01 LT LTPA2015027C patent/LTC1495018I2/lt unknown
- 2015-07-03 FR FR15C0047C patent/FR15C0047I2/fr active Active
- 2015-07-09 NO NO2015016C patent/NO2015016I1/no not_active IP Right Cessation
- 2015-07-10 CY CY2015029C patent/CY2015029I1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005528406A5 (https=) | ||
| CA2482858A1 (en) | Tricyclic thrombin receptor antagonists | |
| RU2006113638A (ru) | Антагонисты рецептора тромбина | |
| JP2016518385A5 (https=) | ||
| AR074165A1 (es) | Antagonistas de heteroalquilo de receptores de prostaglandina d2 y composiciones farmaceuticas | |
| JP2006507355A5 (https=) | ||
| RU2004115114A (ru) | Аналоги гимбацина как антагонисты рецептора тромбина | |
| CA2410177A1 (en) | Thrombin receptor antagonists | |
| EA200800162A1 (ru) | Новые фармацевтические композиции с замедленным высвобождением и способы их получения | |
| JP2015522650A5 (https=) | ||
| JP2010539110A5 (https=) | ||
| JP2014532070A5 (https=) | ||
| CY1112024T1 (el) | Αναστολεις υποδοχεων adp αιμοπεταλιων | |
| CA2498051A1 (en) | Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes | |
| JP2008510828A5 (https=) | ||
| JP2011520967A5 (https=) | ||
| HK1050008A1 (zh) | 杂双环磺胺剂及以其作为血小板腺苷二磷酸(adp)受体抑制剂 | |
| JP2017530959A5 (https=) | ||
| JP2008510691A5 (https=) | ||
| RU2011103454A (ru) | Бициклические гетероциклы в качестве ингибиторов киназы мек | |
| JP2010501478A5 (https=) | ||
| MA29119B1 (fr) | Derives de pyrrolidyle de composes heteroaromatiques servant d'inhibiteurs de phosphodiesterases | |
| JP2013523710A5 (https=) | ||
| CA2540214A1 (en) | 2,4-dioxo-3-quinazolinylaryl sulfonylureas | |
| CA2487365A1 (en) | Piperidine derivatives as potassium channel blockers |